We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Bio-Techne

Bio-Techne Corporation is a developer and manufacturer of high-quality purified proteins and reagent solutions - nota... read more Featured Products: More products

Download Mobile App




Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

By LabMedica International staff writers
Posted on 19 Nov 2024
Print article
Image: The Simple Plex Human Phospho Tau 217 ALZpath assay runs on the Ella automated immunoassay platform (Photo courtesy of Bio-Techne)
Image: The Simple Plex Human Phospho Tau 217 ALZpath assay runs on the Ella automated immunoassay platform (Photo courtesy of Bio-Techne)

Bio-Techne Corporation (Minneapolis, MN, USA) and ALZpath, Inc. (Carlsbad, CA, USA) have entered into a strategic partnership to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.

The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease. By running the Simple Plex Human Phospho Tau 217 ALZpath Assay on the Ella system, researchers will be able to detect the pTau217 signal in less invasive sample collection types, such as plasma samples, in just 90 minutes without any manual intervention, improving efficiency, scalability, and precision while providing the required information to help accelerate clinical decisions.

"Our partnership with ALZpath represents a major step forward in our commitment to advancing neurodegenerative disease research," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We're excited to see the impact that this easy-to-use, hands-free platform will have on advancing research in this critical field."

"As cases of Alzheimer's disease continue to rise around the world, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments," said Chad Holland, CEO at ALZpath. "The integration of our pTau217 antibody into Bio-Techne's advanced immunoassay technology creates a unique toolset that will empower researchers around the world to explore new methods of treatment and validate benefits that may result from those interventions, pushing the industry forward."

Related Links:
Bio-Techne Corporation

ALZpath, Inc.

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Automated Blood Typing System
IH-500 NEXT
New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
New
Flow Cytometer
BF – 710

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Small molecule modulation of protein corona significantly enhances deep plasma proteome profiling (Photo courtesy of Mahmoudi Group)

Smarter Blood Tests Deliver Faster Diagnoses and Improved Outcomes

It has long been established that the earlier a disease is detected, the better the chances for a positive patient outcome. A novel method now offers an in-depth analysis of proteins in plasma, uncovering... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: Photoacoustic images of a splayed vessel structure underlying very light and dark skin tones (Photo courtesy of asquinha, Gubbi, and Bell, doi 10.1117/1.BIOS.2.1.012502)

New Imaging Technique Reduces Skin Tone Bias in Breast Cancer Detection

Breast cancer remains a significant global health issue, and early detection is key to successful treatment. Traditional imaging techniques like mammography often face challenges, particularly for women... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.